Maze Therapeutics, Inc.
MAZE
$7.83
$0.233.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 7.36% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 11.53% | -- | -- | -- | |
| Operating Income | 158.43% | -- | -- | -- | |
| Income Before Tax | 153.18% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 152.02% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 152.02% | -- | -- | -- | |
| EBIT | 158.43% | -- | -- | -- | |
| EBITDA | 164.45% | -- | -- | -- | |
| EPS Basic | 103.47% | -- | -- | -- | |
| Normalized Basic EPS | 163.71% | -- | -- | -- | |
| EPS Diluted | 99.71% | -- | -- | -- | |
| Normalized Diluted EPS | 132.37% | -- | -- | -- | |
| Average Basic Shares Outstanding | 4.77% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 24.60% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
